It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol ...

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...

As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...

In a new study, researchers examined herbal supplements with immune-activating properties that could trigger or worsen ...

Investigators compared the risk of cancer onset in patients with lupus nephritis treatedwith calcineurin inhibitors vs ...

Subcutaneous anifrolumab (Saphnelo) added to standard therapy significantly improves treatment outcomes in patients with ...

Lupus affects women at disproportionately high rates— roughly 9 out of 10 patients are female —and research consistently ...

A regulatory decision is expected by October 2025. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva ®) for the ...

Lupus is often marked by flares, which is when symptoms are usually more obvious.

A doctor advising … sleepaway camp? That’s how a 12-year-old diagnosed with lupus found himself laughing on a high-ropes course as fellow campers hoisted him into the air. “It’s really fun,” said ...